184 related articles for article (PubMed ID: 23448472)
1. Current κ opioid receptor ligands and discovery of a new molecular scaffold as a κ opioid receptor antagonist using pharmacophore-based virtual screening.
Spetea M; Asim MF; Noha S; Wolber G; Schmidhammer H
Curr Pharm Des; 2013; 19(42):7362-72. PubMed ID: 23448472
[TBL] [Abstract][Full Text] [Related]
2. Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands.
Spetea M; Schmidhammer H
Handb Exp Pharmacol; 2022; 271():163-195. PubMed ID: 33454858
[TBL] [Abstract][Full Text] [Related]
3. Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.
Zhou L; Stahl EL; Lovell KM; Frankowski KJ; Prisinzano TE; Aubé J; Bohn LM
Neuropharmacology; 2015 Dec; 99():131-41. PubMed ID: 26160155
[TBL] [Abstract][Full Text] [Related]
4. Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates.
Ko MC; Husbands SM
Handb Exp Pharmacol; 2022; 271():435-452. PubMed ID: 33274403
[TBL] [Abstract][Full Text] [Related]
5. Development of Diphenethylamines as Selective Kappa Opioid Receptor Ligands and Their Pharmacological Activities.
Schmidhammer H; Erli F; Guerrieri E; Spetea M
Molecules; 2020 Nov; 25(21):. PubMed ID: 33147885
[TBL] [Abstract][Full Text] [Related]
6. The Therapeutic Potential of Novel Kappa Opioid Receptor-based Treatments.
Mercadante S; Romualdi P
Curr Med Chem; 2020; 27(12):2012-2020. PubMed ID: 30666905
[TBL] [Abstract][Full Text] [Related]
7. Role of kappa-opioid receptors in stress and anxiety-related behavior.
Van't Veer A; Carlezon WA
Psychopharmacology (Berl); 2013 Oct; 229(3):435-52. PubMed ID: 23836029
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel functionally selective κ-opioid receptor scaffolds.
White KL; Scopton AP; Rives ML; Bikbulatov RV; Polepally PR; Brown PJ; Kenakin T; Javitch JA; Zjawiony JK; Roth BL
Mol Pharmacol; 2014 Jan; 85(1):83-90. PubMed ID: 24113749
[TBL] [Abstract][Full Text] [Related]
9. A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse.
Khan MIH; Sawyer BJ; Akins NS; Le HV
Eur J Med Chem; 2022 Dec; 243():114785. PubMed ID: 36179400
[TBL] [Abstract][Full Text] [Related]
10. Locus coeruleus kappa-opioid receptors modulate reinstatement of cocaine place preference through a noradrenergic mechanism.
Al-Hasani R; McCall JG; Foshage AM; Bruchas MR
Neuropsychopharmacology; 2013 Nov; 38(12):2484-97. PubMed ID: 23787819
[TBL] [Abstract][Full Text] [Related]
11. Development of functionally selective, small molecule agonists at kappa opioid receptors.
Zhou L; Lovell KM; Frankowski KJ; Slauson SR; Phillips AM; Streicher JM; Stahl E; Schmid CL; Hodder P; Madoux F; Cameron MD; Prisinzano TE; Aubé J; Bohn LM
J Biol Chem; 2013 Dec; 288(51):36703-16. PubMed ID: 24187130
[TBL] [Abstract][Full Text] [Related]
12. Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.
Zheng Z; Huang XP; Mangano TJ; Zou R; Chen X; Zaidi SA; Roth BL; Stevens RC; Katritch V
J Med Chem; 2017 Apr; 60(7):3070-3081. PubMed ID: 28339199
[TBL] [Abstract][Full Text] [Related]
13. Kappa-opioid ligands in the study and treatment of mood disorders.
Carlezon WA; Béguin C; Knoll AT; Cohen BM
Pharmacol Ther; 2009 Sep; 123(3):334-43. PubMed ID: 19497337
[TBL] [Abstract][Full Text] [Related]
14. Kinase cascades and ligand-directed signaling at the kappa opioid receptor.
Bruchas MR; Chavkin C
Psychopharmacology (Berl); 2010 Jun; 210(2):137-47. PubMed ID: 20401607
[TBL] [Abstract][Full Text] [Related]
15. Estrogen Regulation of GRK2 Inactivates Kappa Opioid Receptor Signaling Mediating Analgesia, But Not Aversion.
Abraham AD; Schattauer SS; Reichard KL; Cohen JH; Fontaine HM; Song AJ; Johnson SD; Land BB; Chavkin C
J Neurosci; 2018 Sep; 38(37):8031-8043. PubMed ID: 30076211
[TBL] [Abstract][Full Text] [Related]
16. Stress-Induced Reinstatement of Nicotine Preference Requires Dynorphin/Kappa Opioid Activity in the Basolateral Amygdala.
Nygard SK; Hourguettes NJ; Sobczak GG; Carlezon WA; Bruchas MR
J Neurosci; 2016 Sep; 36(38):9937-48. PubMed ID: 27656031
[TBL] [Abstract][Full Text] [Related]
17. How Does Agonist and Antagonist Binding Lead to Different Conformational Ensemble Equilibria of the κ-Opioid Receptor: Insight from Long-Time Gaussian Accelerated Molecular Dynamics Simulation.
An X; Bai Q; Bing Z; Zhou S; Shi D; Liu H; Yao X
ACS Chem Neurosci; 2019 Mar; 10(3):1575-1584. PubMed ID: 30372027
[TBL] [Abstract][Full Text] [Related]
18. Kappa-Opioid Antagonists for Psychiatric Disorders: From Bench to Clinical Trials.
Carlezon WA; Krystal AD
Depress Anxiety; 2016 Oct; 33(10):895-906. PubMed ID: 27699938
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
20. Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats.
Knoll AT; Meloni EG; Thomas JB; Carroll FI; Carlezon WA
J Pharmacol Exp Ther; 2007 Dec; 323(3):838-45. PubMed ID: 17823306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
